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Abstract
Background: Pre-operative evaluation of lung cancer patients relies on calculation of predicted post-operative
(PPO) lung function based on split lung function testing. Pulmonary perfusion (Q) PET/CT can now be performed
by substituting Technetium-99 m labeling of macroaggregated albumin (MAA) with Gallium-68. This study
compares Q PET/CT with current recommended methods of pre-operative lung function assessment.
Methods: Twenty-two patients planned for curative surgical resection (mean FEV1 77 %, SD 21 %; mean DLCO
66 %, SD 17 % predicted) underwent pre-operative Q PET/CT. Sixteen patients also underwent conventional lung
scintigraphy. Lobar and lung split PPO lung function were calculated using Q PET/CT and current recommended
methods, i.e. calculation based on anatomical segments for lobar function, and conventional perfusion scan for
pneumonectomy. Bland-Altman statistics were used to calculate agreement between methods for PPO FEV1 and
PPO DLCO.
Results: While mean split lobar functions were comparable, there was variation on an individual level between
Q PET/CT and the anatomical method, with absolute difference over 5 % and 10 % in 37 % and 11 % of patients,
respectively. For lobectomy the mean difference in PPO FEV1 was−1.2, but limits of agreement were−10 to 8.1 %.
For DLCO, values were−1.1 % and−9.7 to 7.5 %, respectively. For pneumonectomy, PPO FEV1 values were−0.4
and−5.9 to 5.1 %. For DLCO, values were 0.3 % and−5.1 to 4.6 %.
Conclusions: While anatomic estimation provides “fixed” results, split lobar functions computed with Q PET/CT
vary widely, reflecting the intra and inter-individual variability of regional lung function. Further studies to assess the
role of Q PET/CT in predicting peri-operative risk in lung cancer patients planned for lobectomy are warranted.
Keywords: PET/CT, Perfusion, Gallium-68, Surgery, Lung cancer
Background
Lung cancer is the leading cause of cancer-related mor-
tality worldwide [1]. In individuals with stage I and II
non-small cell lung cancer, surgery is the treatment of
choice if the tumour is considered resectable and the
patient is considered fit for surgery [2]. Despite
refinements in lung resection techniques, post-operative
morbidity and mortality are significant and only 20–
25 % of patients will eventually undergo surgery [3].
Most patients with lung cancer are former or current
smokers, which increases operative risk, particularly due
to chronic obstructive pulmonary disease (COPD). The
dilemma then arises of whether to perform potentially
life saving surgery in a patient who has an increased risk
of operative mortality or of significant post-operative
dyspnoea. Therefore, accurate evaluation of pre-
operative lung function is imperative to estimate the risk
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of both short and long-term post-operative adverse
events, and to select patients who will derive maximum
benefit with minimal risk from surgery [3].
Current guidelines recommend a series of investiga-
tions to risk stratify patients [4–6]. Initial tests include
measurement of the forced expiratory volume in 1 sec-
ond (FEV1) and diffusion capacity of the lung for carbon
monoxide (DLCO). However, these tests alone are lim-
ited because they do not take into account the high de-
gree of inter-patient variability including regional
heterogeneity of any underlying lung disease, the extent
of lung to be resected, and the contribution of the
portion of lung to be removed to overall lung function.
Accordingly, split lung function testing is used in con-
junction with FEV1 and DLCO to assess the functional
contribution of the lung to be resected and to calculate
a predicted post-operative (PPO) value of lung function.
The American College of Chest Physicians (ACCP)
guidelines recommend that both FEV1 and DLCO be
measured and that both PPO FEV1 and PPO DLCO are
calculated in all patients with lung cancer being consid-
ered for surgery [6]. To compute PPO values, guidelines
recommend the use of conventional perfusion scintig-
raphy using macroaggregated albumin (MAA) labelled
with Technetium-99 m (99mTc) before pneumonec-
tomy or an anatomic method based on counting the
number of functional segments to be removed before
lobectomy [6].
Our group has demonstrated the feasibility of transi-
tioning from conventional single photon techniques to
positron emission tomography (PET) technology for
lung scintigraphy [7]. 99mTc can be substituted by
Gallium-68 (68Ga), a positron-emitting radionuclide, to
label MAA, which are trapped in the lung capillaries so
that local concentration is related to the regional pul-
monary blood flow. The regional distribution of perfu-
sion within the lungs is then possible using PET
technology. This offers a unique opportunity to improve
the diagnostic performance of lung perfusion imaging,
due to the higher sensitivity, spatial resolution, speed of
acquisition and, most importantly, quantitative capability
of PET in comparison to conventional scintigraphy [8].
In a recent study, we showed a high degree of correl-
ation between ventilation-perfusion PET/CT functional
lungs volumes and pulmonary function tests (PFTs) pa-
rameters [9], suggesting significant potential in manage-
ment of patients with pulmonary disease. We have also
explored this technology for individualising radiotherapy
treatment plans [10, 11] and assessing radiation injury to
lungs [10, 12].
In order to assess the potential utility of this new tech-
nology for pre-operative assessment of lung cancer pa-
tients, we aimed to compare the information provided
by perfusion (Q) PET/CT imaging with that of current
recommended methods, when assessing split lung func-
tion and computing PPO values of lung function in lung
cancer patients being considered for surgery.
Methods
Patients
In this retrospective series, patients referred to our PET
centre for Q PET/CT imaging as part of their preopera-
tive evaluation for lung surgery by a single surgeon were
identified between 2013 and 2014. Patients with biopsy
proven lung malignancy were planned for surgery with
curative intent based on exclusion of distant metastatic
disease by FDG PET/CT. Patients with clinically sus-
pected lung malignancy were planned for intraoperative
frozen section to confirm presumed malignancy prior to
resection with curative intent. All patients underwent
PFTs and gated perfusion PET/CT as part of pre-
treatment evaluation. 16 patients also underwent planar
lung scintigraphy using 99mTc-MAA. Three patients
were ‘salvage cases’ ie they had undergone chemo radi-
ation with curative intent months prior and had failed
locally. Out of the 22 patients, 13 underwent a lobec-
tomy, 4 a segmentomy, 1 a pneumonectomy and 4 pa-
tients did not have curative surgery, respectively. The
study was performed in accordance with the Declaration
of Helsinki and was approved by the institutional ethics
committee (Number 13/152).
Pulmonary function tests
Spirometry was performed in accordance with the joint
European Respiratory Society (ERS) and American Thor-
acic Society (ATS) clinical practice guidelines [13, 14].
Post bronchodilator FEV1 was expressed as an absolute
value and a percentage of predicted and DLCO as a per-
centage of predicted.
Q PET/CT protocol
All patients underwent a respiratory-gated (4D) PET-CT
lung perfusion scan using a procedure that we have pre-
viously described [15]. Patients were imaged on a GE
Discovery 690 PET/CT scanner (GE Medical Systems
Milwaukee, WI, USA) after injection of approximately
50 MBq of 68Ga-MAA [7]. The perfusion PET was ac-
quired as a two-bed acquisition encompassing the apex
to base of both lungs planned by a scout CT. Each bed
position was acquired for 5 min.
Split lung function calculation
Conventional methods
As a reference standard, lobar and lung split function
were computed according to current recommended
methods, using an anatomic estimation before lobec-
tomy and by a conventional planar perfusion scan before
pneumonectomy [6].
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For lobar split function assessment, the following
equation was used:
Relative function ¼ Number of functional or unobstructed
lung segments in the lobe of interest =
total number of functional or
unobstructed lung segments:
The total number of segments for both lungs was 19
(10 in the right lung: 3 in the upper, 2 in the middle, 5
in the lower; and 9 in the left lung: 3 in the upper div-
ision, 2 in the lingula and 4 in the lower) [16].
For lung split function assessment, conventional pla-
nar perfusion scintigraphy was used as follow:
Relative function ¼ perfusion in the lung of interest =
total lung perfusion
Q PET/CT
Lobes were delineated on CT images using MIMimage
analysis software (MIM 5.4.4; MIMSoftware, Cleveland,
OH, USA). In the left upper lobe, the lingula and the left
upper division were delineated. Segmentation was subse-
quently applied to the PET images and the following
equation was used to compute split lung function for
each lobe and lung:
Relative function ¼ perfusion in the region of interest =
total lung perfusion
PPO lung function calculation
PPO FEV1 as an absolute value (in litres) and a percent
predicted, and PPO DLCO as a percent predicted, were
computed for all 22 patients for 2 scenarios-1 assuming
each would undergo pneumonectomy for the index le-
sion and for this scenario we compared Q PET/CT with
planar VQ (in accordance with current guidelines) and
in the second scenario we assumed each patient would
undergo lobectomy for the index lesion and compared
Q PET/CT with the anatomical method for calculating
post op lung function (as is recommended in current
guidelines).
PPO values were calculated using the following
equations:
PPO FEV1 ¼ pre−operative FEV1 x fraction of total
function to be removed
PPO DLCO ¼ pre−operative DLCO x fraction of
total function to be removed
Statistical analysis
All statistical tests were carried out using GraphPad
Prism 5 (La Jolla, CA, USA). The mean, standard
deviation, and ranges were computed for all split lung
function and PPO PFTs values. Limits of agreement be-
tween PPO PFTs values were analysed by means of
Bland-Altman analysis.
Results and discussion
Twenty-two patients (11 males, 11 females; mean age
67 years, range 38–82 years) were analysed. The mean
pre-operative FEV1 was 2.04 L (SD: 0.65 L; range: 1.00–
3.26 L) and the mean pre-operative percentage of pre-
dicted FEV1 was 77 % (SD: 21 %; range: 33–123 %). The
mean pre-operative percentage of predicted DLCO was
66 % (SD: 17 %; range: 39–110 %). Primary lesion was
located in the right upper lobe in 9 patients, the right
middle lobe in 2, the right lower lobe in 4, the left upper
division in 6, and the left lower lobe in 1 patient.
Split lung function
Mean of split lung functions computed with Q PET/CT
and the reference methods were not statically different.
However, standard deviation and range of split lobar
function were much wider using Q PET/CT rather than
the anatomical method (See Table 1 and Fig. 1). The ab-
solute difference in lobar split function between Q PET/
CT and the anatomic method was greater than 5 % of
total lung function in 49 of 132 lobes (37 %), and greater
than 10 % in 15 of 132 of lobes (11.4 %). The absolute
difference in lung split function between Q PET/CT and
planar perfusion scan was greater than 5 % of total lung
function in 19 % of lungs but never more than 10 %.
Figure 2 shows an example of different lobar split func-
tion using Q PET/CT or the anatomic estimation.
Table 1 Comparison of split function computed with Q PET/CT
and the recommended methods (anatomic estimation for lobar
split function, conventional perfusion scan for lung split
function) for all lobes and lungs regardless of index lesion
Anatomic estimation Q PET/CT
Mean sd Range Mean sd Range
RUL 15 3 0–16 15 8 1–31
RML 11 0 11–13 9 4 3–17
RLL 27 1 26–31 27 6 14–37
LUD 16 1 16–19 16 6 5–25
Lingula 11 0 11–13 7 2 5–12
LLL 21 1 21–25 26 11 9–48
Index lobe 17 6 0–26 15 7 1–37
Planar perfusion scan Q PET/CT
Mean sd Range Mean sd Range
RL 49 10 29–59 51 11 23–54
LL 51 10 41–71 49 11 36–77
Index lung 46 9 29–59 45 11 23–61
Results are expressed as percentage of total lung function
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PPO lung function after lobectomy
The mean, standard deviation and range of Predicted
post-operative % predicted FEV1, absolute FEV1 and
DLCO, as calculated by the anatomical method or Q
PET/CT are presented in Table 2. The mean of the differ-
ence and the limits of agreement between PPO as % pre-
dicted FEV1 and % predicted DLCO are shown in Fig. 3.
PPO lung function after pneumonectomy
The mean, standard deviation and range of PPO % pre-
dicted FEV1, FEV1 and % predicted DLCO using the
planar scintigraphy or Q PET/CT are presented in
Table 3. The mean of the difference and the limits of
agreement between PPO as % predicted FEV1 and %
predicted DLCO are shown in Fig. 3.
Discussion
In the present study, we found that lobar lung split func-
tions calculated by Q PET/CT differ from that estimated
with the current recommended methodology [6]. While
anatomic estimation provides “fixed” results, relative
lobar functions vary widely using Q PET/CT, consistent
Fig. 1 Paired split lung function using Q PET/CT and the recommended methods, i.e. the anatomical method for split lobar function, and planar
scintigraphy for relative lung function
Fig. 2 Example of discordant lobar split function distribution
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with known inter-individual variability of regional lung
function. The impact of Q PET/CT when calculating
PPO lung function was less marked, but not trivial clin-
ically, in this small series including patients without sig-
nificant lung function impairment. On the other hand,
Q PET/CT does not seem to provide major differences
as compared with conventional planar scintigraphy in
patients being assessed for pneumonectomy. This is not
entirely unexpected since both reflect the ratio of perfu-
sion to the left and right lungs.
We compared lobar split function computed with Q
PET/CT and the current recommended method, i.e. an
anatomical approach based on counting the number of
functional segments to be removed [6]. While mean
lobar split functions were very close with both methods,
standard deviations and ranges were much wider using
Q PET/CT, with lobar relative function being either
higher or lower than that predicted with the anatomic
method. Overall, absolute difference in lobar split func-
tion between both methods was greater than 5 % of total
lung function in 37.1 % lobes and greater than 10 % in
11.4 % of lobes. Given the heterogeneity of regional lung
function, especially in patients with COPD [17], these
results are likely to be more representative of the inter-
individual variability of regional lung function as com-
pared with the fairly “fixed” results provided by the ana-
tomical method.
The question then arises regarding the impact of such
results when estimating the risk of adverse surgical
events, i.e. when calculating PPO FEV1 and DLCO. In
the present study, the limits of agreement between PPO
values of lung function predicted from Q PET/CT and
the anatomical method were up to 10 % (PPO
FEV1:−10–8.1 % 1; PPO DLCO:−9.7–7.5 %). These
limits of agreement appear large and clinically significant
in the setting of a pre-operative workup of a lung cancer
patients being considered for surgery. In a study of 1,428
subjects undergoing lung resection, Alam et al. found a
10 % increase in the risk of complications for every 5 %
decrement in PPO lung function [18]. In the ACCP
guidelines for physiologic evaluation of lung cancer pa-
tients before surgery, a functional algorithm based on
measurement of PPO FEV1 and PPO DLCO in all pa-
tients is proposed. In particular, a cut-off value of 60 %
is proposed for both PPO FEV1 and PPO DLCO to se-
lect patients with a low risk for surgery. If one parameter
Table 2 PPO PFTs values after lobectomy of the index lobe
Anatomical Q PET/CT
Mean sd Range Mean sd Range
FEV1 % pred 64 19 26–110 65 19 27–107
FEV1 L 1.69 0.52 0.79–2.65 1.72 0.54 0.82–2.81
DLCO % pred 55 15 33–93 56 15 35–90
Fig. 3 Bland-Altman plot of PPO FEV1 and DLCO as percent predicted, after lobectomy or pneumonectomy. The bias and the limits of
agreement between PPO values are displayed in each graphics
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is lower than 60 %, further testing is recommended. In
our series of 22 patients, 3 would have had a different
management using Q PET/CT rather than the anatom-
ical method when computing PPO values. In addition,
using the historical 40 % cut-off to select patients
suitable for surgery with an acceptable clinical outcome,
decision-making would have been different in 2 add-
itional patients. Nevertheless, there were no patients
with PPO FEV1 or PPO DLCO lower than 30 %,
which has been recently described as a more adapted
cut-off [6, 19].
When simulating a pneumonectomy of the index lung,
the impact of transitioning from conventional planar
scintigraphy to PET technology was less convincing.
Mean, standard deviation and graphical analysis of split
lung functions demonstrate close results with both
methods. Limits of agreement were smaller (PPO
FEV:−5.9–5.1 % 1; PPO DLCO:−5.1–4.6 %) as compared
with a lobectomy. However, both lung and lobar split
lung function calculation may be advantageous in pa-
tients with borderline lung function to compare the
post-operative risk of both pneumonectomy and lobec-
tomy to aide surgical decision making in the event that
intraoperative findings preclude safe oncological lobec-
tomy. In that setting, Q PET/CT may offer the advan-
tage of providing an accurate assessment of the risk of
both types of surgery in a single test.
Perfusion PET/CT imaging represents a promising
alternative to current methods owing to several advan-
tages. The acquisition time is around six minutes less
than for conventional planar scintigraphy using a dual-
detector gamma camera but provides fully tomographic
images of higher resolution. SPECT/CT can provide
tomographic images but has a significantly longer
acquisition time and provides lower resolution. As with
conventional scintigraphy, there are no known contrain-
dications or acute side effects (allergy) associated with
the radiotracers. The effective radiation dose of the scan
is low, approximately 1 mSv for the PET acquisition plus
an additional 1–2 mSv for the low dose CT component.
In addition, the number of particles typically used for a
fresh 68Ga MAA administration is approximately half of
that used for a fresh 99m Tc-MAA administration, which
may be an advantage of VQ PET as compared with VQ
SPECT in patients with pulmonary hypertension. In our
institution, there is no significant increase in cost or
processing as regards Ga68-MAA labelling but this may
vary according to local expertise and facilities. Finally,
68Ga is produced by an on-site generator enabling on-
demand availability similar to 99mTc, but with a longer
shelf-life of 9–12 months versus 1–2 weeks for 99mTc
generator. The 68Ga generator is increasingly available
owing to its use for neuroendocrine [20] and prostate
cancer imaging. With PET/CT and 68Ga becoming in-
creasingly available, we envisage that widespread adop-
tion of V/Q PET/CT could become a reality as part of a
more general more of diagnostic nuclear medicine to-
wards PET/CT technology [8].
This study has several limitations. First, PPO lung
functions were not correlated with actual post-operative
lung function. Nevertheless, there is evidence than PPO
values are prognostic factors for short and long-term
postoperative risk rather than accurate predictors of
post-operative lung function [21]. In particular, many
studies have reported an improvement in pulmonary
function after lung surgery in some patients with COPD
in keeping with a lung volume reduction effect [22]. On
the other hand, the risk of post-operative complications
has been linked to PPO lung function [18]. In this small
series, we did not assess the prognostic value of PPO
PFT values computed using Q PET/CT. As a first neces-
sary step, we showed that this new technology provides
different information as compared with current recom-
mended methods, which justify, from our point of view,
further studies whose objective will be to compare the
prognostic value of methodologies in terms of post-
operative morbidity and mortality. Second, we did not
compare Q PET/CT results to other modalities such as
V/Q SPECT/CT [23], quantitative CT [24] or MRI [25],
which have also been proposed to predict post-operative
lung function. However, we compared Q PET/CT to the
currently recommended methodologies, which are likely
to be the most commonly used method in clinical prac-
tice. Third, this study was limited to a small series of pa-
tients and included some patients with non-impaired
lung function. Again, this was performed in keeping with
clinical guidelines. Nevertheless, it is likely that the use-
fulness of such a modality that aims at providing a more
personalized approach would be greater in patients with
borderline lung function. Finally, for a variety of reasons
including patient preference and logistic considerations,
only approximately 1/3 of patients assessed for resection
Table 3 PPO PFTs values after pneumonectomy of the index lung
Planar Q PET/CT
Mean sd Range Mean sd Range
FEV1 % pred 44 11 27–68 44 12 26–72
FEV1 L 1.10 0.41 0.58–2.12 1.12 0.46 0.59–2.25
DLCO % pred 37 12 20–63 37 13 22–67
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during the inclusion period underwent Q PET/CT as-
sessment. A selection bias is therefore a possibility.
However, this was a heterogeneous group of patients,
likely broadly reflecting the surgeons’ standard practice.
Conclusions
To the best of our knowledge, this study is the first
assessing Q PET/CT to compute split lung function and
predict PPO lung function in lung cancer surgery pa-
tients. In the pre-therapeutic work up of patients under-
going lobectomy, Q PET/CT provides different results
compared to the anatomical estimation, with a wider
range of results that may be more representative of the
inter-individual variability of regional lung function.
Further larger studies are now needed to assess if Q
PET/CT allows better prediction of short and long-term
outcome and may influence management of lung cancer
patients undergoing surgery.
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